<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>These investigations characterised the cerebrovascular effects of an endothelin <z:chebi fb="209" ids="16000,53460">ETA</z:chebi>-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> PD156707 in <z:mpath ids='MPATH_458'>normal</z:mpath> and ischaemic cat brain </plain></SENT>
<SENT sid="1" pm="."><plain>A dose of PD156707 that inhibited the effects of exogenous endothelin-1 was established in nonischaemic cerebral resistance arterioles </plain></SENT>
<SENT sid="2" pm="."><plain>Perivascular microapplication of the <z:chebi fb="0" ids="51451">endothelin-receptor antagonist</z:chebi> PD156707 (0.03-3 microM) had a minimal effect on nonischaemic pial resistance arterioles </plain></SENT>
<SENT sid="3" pm="."><plain>The perivascular co-application of PD156707 and ET-1 (10 nM) effected a dose-dependent attenuation of the ET-1 vasoconstrictive response (IC50 = 0.1 microM) </plain></SENT>
<SENT sid="4" pm="."><plain>Intravenous administration of PD156707 (3 mumol/kg bolus + 5 mumol/kg/h infusion) attenuated the vasoconstriction elicited by perivascular ET-1 (10 nM) in <z:mpath ids='MPATH_458'>normal</z:mpath> pial arterioles (ET-1 vasoconstriction: -37 +/- 13% from preinjection baseline; after intravenous PD156707: 6 +/- 10% from preinjection baseline) </plain></SENT>
<SENT sid="5" pm="."><plain>In the focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> studies, cerebral perfusion was measured in the suprasylvian and ectosylvian gyri (by laser Doppler flowmetry) </plain></SENT>
<SENT sid="6" pm="."><plain>Occlusion of the middle cerebral artery reduced cerebral perfusion in the suprasylvian and ectosylvian gyri by approximately 50% </plain></SENT>
<SENT sid="7" pm="."><plain>Intravenous administration of PD156707 (3 mumol/kg bolus + 5 mumol/kg/h infusion), initiated 30 min after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, effected a progressive increase in cerebral perfusion up to preocclusion baseline levels, whereas cerebral perfusion in vehicle-treated animals did not vary from its postocclusion level </plain></SENT>
<SENT sid="8" pm="."><plain>In these animals, the intravenous administration of PD156707 reduced the hemispheric volume of ischaemic damage by 45% (vehicle: 2,376 +/- 1,107 mm3; PD156707: 1,307 +/- 548 mm3; p &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Our investigations indicate that endothelin receptor antagonism may be a new therapeutic strategy for the amelioration of focal ischaemic damage </plain></SENT>
</text></document>